Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Seattle Genetics (SGEN) -- Ignore unavailable to you. Want to Upgrade?

To: mopgcw who wrote (50)	9/8/2004 11:30:26 AM
From: keokalani'nui	Respond to of 161

<toying with it for a while, but have not been able to pull the trigger for some unknown reason.> I think the problem is that it is hard enough to buy into a BT with one questionable lead program that management just seems hell bent to advance no matter what, much less two. Almost doesn't matter what comes after. As for the loss of CSO, commentators quoted in the PI today are saying it is a loss for sgen, gain for zymo--and that the guy may have upper mgmt aspirations more likely to be met at zymo. Could just be what sgen needs, however, a fresh broom.